ArticlePharmaceutics2024

IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma.

Zikang Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.